{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:33:59Z","timestamp":1792503239303,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merck, BMS, and Scientific Advisor"},{"name":"ARMO BioSciences"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012431","name":"Celldex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007210","name":"Varian","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ijrobp.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T21:49:08Z","timestamp":1537048148000},"page":"142-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"103","author":[{"given":"Luke R.G.","family":"Pike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon A.","family":"Mahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Spektor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Cagney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayal A.","family":"Aizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Rahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Balboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.09.010_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib6","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib7","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti\u2013CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","article-title":"B70 antigen is a second ligand for CTLA-4 and CD28","volume":"366","author":"Azuma","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.7694363","article-title":"Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation","volume":"262","author":"Freeman","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2014.03.024","article-title":"Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012","volume":"112","author":"Barton","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2017.3808","article-title":"Clinical outcomes in patients with metastatic lung cancer treated with PD-1\/PD-L1 inhibitors and thoracic radiotherapy","volume":"4","author":"Hwang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib16","first-page":"1","article-title":"Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40425-016-0149-6","article-title":"A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"4","author":"Crocenzi","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: Modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","article-title":"The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma","volume":"38","author":"Wild","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ygyno.2015.11.013","article-title":"Lymphopenia and its association with survival in patients with locally advanced cervical cancer","volume":"140","author":"Wu","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib24","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib25","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2017.07.033","article-title":"Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1\/PD-L1 inhibitors)","volume":"84","author":"Sun","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2017.06.006","article-title":"Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation","volume":"124","author":"Pike","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib28","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung v5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib30","first-page":"200","article-title":"Characteristics of the lymphopenia induced by radiotherapy","volume":"23","author":"Campbell","year":"1976","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib31","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(72)91091-4","article-title":"Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma","volume":"299","author":"Stjernsw\u00e4rd","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib32","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/1097-0142(197603)37:3<1417::AID-CNCR2820370324>3.0.CO;2-N","article-title":"The effect of radiation therapy on lymphocyte subpopulations in cancer patients","volume":"37","author":"Raben","year":"1976","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: Changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib35","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib36","series-title":"Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study","author":"Theelen","year":"2018"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib37","unstructured":"McBride SM, Sherman EJ, Tsai CJ, et\u00a0al. A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). 2018 ASACO Annual Meeting Abstracts. In: American Society of Clinical Oncology. Chicago, IL; 2018."},{"key":"10.1016\/j.ijrobp.2018.09.010_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jtcvs.2008.05.046","article-title":"Neutrophil\/lymphocyte ratio and its association with survival after complete resection in non\u2013small cell lung cancer","volume":"137","author":"Sarraf","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ijrobp.2009.11.062","article-title":"Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: Principal component analysis on high dimensional data","volume":"78","author":"Liang","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib40","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.22300","article-title":"Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site","volume":"107","author":"Seve","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/089686080102100207","article-title":"Long-term CAPD survival and analysis of mortality risk factors: 12-year experience of a single Mexican center","volume":"21","author":"Cueto-Manzano","year":"2001","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib43","doi-asserted-by":"crossref","first-page":"e23288","DOI":"10.4161\/onci.23288","article-title":"Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients","volume":"2","author":"Iversen","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/neuonc\/noq204","article-title":"Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme","volume":"13","author":"Fadul","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/neuonc\/noq157","article-title":"Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma","volume":"13","author":"Sampson","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib46","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2015.180","article-title":"Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients","volume":"112","author":"Ferrucci","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma","volume":"6","author":"Lalani","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib48","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib49","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-015-2037-1","article-title":"Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma","volume":"127","author":"Mendez","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib51","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","article-title":"Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma","volume":"92","author":"Huang","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib52","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib53","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/cncr.31294","article-title":"Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study","volume":"124","author":"Guckenberger","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1470-2045(11)70384-9","article-title":"Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: A phase 1\u20132 trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2018.09.010_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618337556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618337556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T17:58:42Z","timestamp":1604944722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618337556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0360301618337556"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.010","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}